Shanghai Asymchem Biotechnology Development, a wholly-owned subsidiary of China-based drug developer Asymchem Laboratories (Tianjin), has entered into an agreement to raise up to 2.5 billion yuan ($392.2 million) from investors including private equity (PE) firm Hillhouse Capital Group.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
